Download PDF
Planta Med 2017; 83(03/04): 292-299
DOI: 10.1055/s-0042-112128
Pharmacokinetic Investigations
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

In Vitro Regio- and Stereoselective Oxidation of β-Ionone by Human Liver Microsomes

Shinsuke Marumoto
1   Joint Research Center, Kinki (Kindai) University, Kowakae, Higashiosaka-shi, Osaka, Japan
,
Ryoyu Shimizu
2   Department of Applied Chemistry, Faculty of Science and Engineering, Kinki (Kindai) University, Kowakae, Higashiosaka-shi, Osaka, Japan
,
Genzoh Tanabe
3   Pharmaceutical Research and Technology Institute, Kinki (Kindai) University, Higashi-osaka, Osaka, Japan
,
Yoshiharu Okuno
4   Department of Materials Science, Wakayama National College of Technology, Gobo, Wakayama Japan
,
Mitsuo Miyazawa
2   Department of Applied Chemistry, Faculty of Science and Engineering, Kinki (Kindai) University, Kowakae, Higashiosaka-shi, Osaka, Japan
5   Graduate School of Materials Science Nara Institute of Science and Technology, Ikoma, Nara, Japan
› Author Affiliations
Further Information

Publication History

received 23 March 2016
revised 22 June 2016

accepted 06 July 2016

Publication Date:
30 August 2016 (online)

    Permissions and Reprints

Abstract

The metabolism of the norisoprenoid β-ionone was investigated in vitro using human liver microsomes and 11 different recombinant cytochrome P450 enzymes expressed in Trichoplusia ni cells. β-Ionone was found to be oxidized via 4S-hydroxylation by CYP2B6 in human liver microsomes. CYP1A2 also regioselectively catalyzed the hydroxylation of β-ionone to yield 4-hydroxylation; this conversion was not stereoselective. Further kinetic analysis revealed that CYP2B6 exhibited the highest activity for β-ionone 4-hydroxylation. Kinetic analysis showed that K m and V max for oxidation of β-ionone by CYP1A2 and CYP2B6 was 107.9 ± 36.0 µM and 3200.3 ± 323.0 nmol/min/nmol P450 and 5.6 ± 1.2 µM and 572.8 ± 29.8 nmol/min/nmol P450, respectively. The reaction rates observed using human liver microsomes and recombinant CYP2B6 were very high compared with those of other CYP2B6 substrates reported thus far. These results suggest that β-ionone, a norisoprenoid present in nature, is one of the effective substrates for CYP2B enzymes in human liver microsomes. To the best of our knowledge, this is the first time that 4-hydroxy β-ionone has been described as a human metabolite of β-ionone.

Key words

β-ionone - human liver microsome - cytochrome P450 - regio- and stereoselective oxidation - 4-hydroxy-β-ionone
 

  • References

  • 1 Kjeldsen F, Christensen LP, Edelenbos M. Changes in volatile compounds of carrots (Daucus carota L.) during refrigerated and frozen storage. J Agric Food Chem 2003; 51: 5400-5407
    CrossrefPubMedGoogle Scholar
  • 2 Giuggioli NR, Briano R, Baudino C, Peano C. Effects of packaging and storage conditions on quality and volatile compounds of raspberry fruits. CYTA-J Food 2015; 13: 512-521
    PubMedGoogle Scholar
  • 3 Kebede BT, Grauwet T, Mutsokoti L, Palmers S, Vervoort L, Hendrickx M, Van Loey A. Comparing the impact of high pressure high temperature and thermal sterilization on the volatile fingerprint of onion, potato, pumpkin and red beet. Food Res Int 2014; 56: 218-225
    CrossrefPubMedGoogle Scholar
  • 4 Elson CE, Yu SG. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables. J Nutr 1994; 124: 607-614
    PubMedGoogle Scholar
  • 5 Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant warfare, molecular drive and human genetic differences in drug oxidation. Trends Genet 1990; 6: 182-186
    CrossrefPubMedGoogle Scholar
  • 6 Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabroo RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Goto O, Okuda K, Nebert DW. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1-51
    CrossrefPubMedGoogle Scholar
  • 7 Khojasteh-Bakh SC, Chen W, Koenig LL, Peter RM, Nelson SD. Metabolism of (R)-(+)-pulegone and (R)-(+)-menthofuran by human liver cytochrome P-450s: evidence for formation of a furan epoxide. Drug Metab Dispos 1999; 27: 574-580
    PubMedGoogle Scholar
  • 8 Thomassen D, Slattery JT, Nelson SD. Contribution of menthofuran to the hepatotoxicity of pulegone: assessment based on matched area under the curve and on matched time course. J Pharmacol Exp Ther 1988; 244: 825-829
    PubMedGoogle Scholar
  • 9 Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1989; 40: 243-288
    PubMedGoogle Scholar
  • 10 Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991; 4: 391-407
    CrossrefPubMedGoogle Scholar
  • 11 Guengerich FP. Human cytochrome P-450 enzymes. Life Sci 1992; 50: 1471-1478
    CrossrefPubMedGoogle Scholar
  • 12 Miyazawa M, Shindo M, Shimada T. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from Eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes. Drug Metab Dispos 2001; 29: 200-205
    PubMedGoogle Scholar
  • 13 Miyazawa M, Shindo M, Shimada T. Metabolism of (+)- and (−)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Drug Metab Dispos 2002; 30: 602-607
    CrossrefPubMedGoogle Scholar
  • 14 Miyazawa M, Gyoubu K. Metabolism of (+)-fenchone by CYP2A6 and CYP2B6 in human liver microsomes. Biol Pharm Bull 2006; 29: 2354-2358
    CrossrefPubMedGoogle Scholar
  • 15 Gyoubu K, Miyazawa M. In vitro metabolism of (−)-camphor using human liver microsomes and CYP2A6. Biol Pharm Bull 2007; 30: 230-233
    CrossrefPubMedGoogle Scholar
  • 16 Bell SG, Dale A, Rees NH, Wong LL. Cytochrome P450 class I electron transfer system from Novosphingobium aromaticivorans . Appl Microbiol Biotechnol 2010; 86: 163-175
    CrossrefPubMedGoogle Scholar
  • 17 Celik A, Flitsch SL, Turner NJ. Efficient terpene hydroxylation catalysis based upon P450 enzymes derived from Actinomycetes. Org Biomol Chem 2005; 3: 2930-2934
    CrossrefPubMedGoogle Scholar
  • 18 Bylund J, Kunz T, Valmsen K, Oliw EH. Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J Pharmacol Exp Ther 1998; 284: 51-60
    PubMedGoogle Scholar
  • 19 Wrighton S, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIA5 (HLp3). Mol Pharmacol 1990; 38: 207-213
    PubMedGoogle Scholar
  • 20 Duiske M, Benz D, Peiffer TH, Bloemeke B, Hollender J. Metabolism of Δ3-carene by human cytochrome P450 enzymes: identification and characterization of two new metabolites. Curr Drug Metab 2005; 6: 593-601
    CrossrefPubMedGoogle Scholar
  • 21 Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 1999; 9: 295-306
    CrossrefPubMedGoogle Scholar
  • 22 Chang TKH, Bandiera SM, Chen J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 2003; 31: 7-10
    CrossrefPubMedGoogle Scholar
  • 23 Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14: 225-238
    CrossrefPubMedGoogle Scholar
  • 24 Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28: 1222-1230
    PubMedGoogle Scholar
  • 25 Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro . Drug Metab Dispos 2004; 32: 626-631
    CrossrefPubMedGoogle Scholar
  • 26 Walsky L, Astuccio AV, Obach RS. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol 2006; 46: 1426-1438
    CrossrefPubMedGoogle Scholar
  • 27 Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 2008; 36: 1594-1605
    CrossrefPubMedGoogle Scholar
  • 28 Nakajima M, Yoshid R, Shimada N, Yamazaki H, Yokoi T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 2001; 29: 1110-1113
    PubMedGoogle Scholar
  • 29 Kim H, Kim KB, Ku HY, Park SJ, Choi H, Moon JK, Park BS, Kim JH, Yea SS, Lee CH, Lee HS, Shin JG, Liu KH. Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China. Drug Metab Dispos 2008; 36: 1010-1015
    CrossrefPubMedGoogle Scholar
  • 30 Chang TKH, Webe RGF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637
    PubMedGoogle Scholar
  • 31 Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28: 1176-1183
    PubMedGoogle Scholar
  • 32 Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, Blievernicht J, Saussele T, Gunthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81: 557-566
    CrossrefPubMedGoogle Scholar
  • 33 More GP, Bhat SV. Facile lipase catalysed syntheses of (S)-(+)-4-hydroxy-β-ionone and (S)-(+)-4-hydroxy-β-damascone: chiral flavorants and synthons. Tetrahedron Lett 2003; 54: 4148-4149
    PubMedGoogle Scholar
  • 34 Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996; 277: 321-332
    PubMedGoogle Scholar
  • 35 Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Dispos 2008; 23: 412-420
    CrossrefPubMedGoogle Scholar